Tuesday, September 16, 2014 Last update: 8:33 AM
FreshNews.com - All Company Technology News Since 1996

Afaxys Pharmaceuticals Products Now Available Nationwide; OCs Placed on Pennsylvania Medicaid's Preferred Oral Contraceptives List

Companies mentioned in this article: Afaxys Pharmaceuticals

CHARLESTON, SC -- (Marketwired) -- 07/30/14 -- Three FDA-approved oral contraceptives from Afaxys Pharmaceuticals, a division of Afaxys, Inc., (www.afaxys.com/pharma) are now preferred OCs, as per a recent ruling by Pennsylvania's Medicaid system.

The three Afaxys Pharmaceuticals generic contraceptives now available throughout the nation are:

  • Aubra™ /AW--bruh/ (Levonorgestrel and Ethinyl Estradiol Tablets, USP 0.1mg/0.02mg), generic equivalent to Lutera® and compares to these monophasic regimens: Sronyx®, Aviane®, Falmina®, Lessina®, Levlite®, and Orsythia®,
  • Chateal® \shah--TEEL\ (Levonorgestrel and Ethinyl Estradiol tablets USP, 0.15 mg/0.03mg), generic equivalent to Nordette® and compares to these monophasic regimens: Levora®, Portia®, Altavera®, and Marlissa®, and
  • Lyza™ /LI--za/ (Norethindrone Tablets USP, 0.35 mg), generic equivalent to Ortho Micronor® and compares to these monophasic regimens: Nora-BE®, Errin®, Heather®, Jolivette®, Camila® and norethindrone.

All three contraceptives are indicated for the prevention of pregnancy in women who elect to use an oral contraceptive for contraception. These products do not protect against the transmission of HIV (AIDS) and other sexually transmitted diseases. Cigarette smoking increases the risk of serious cardiovascular disease. Women who use oral contraceptives should be strongly advised not to smoke. Please see full prescribing information at https://pharma.afaxys.com

Cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use. This risk increases with age and with the extent of smoking (in epidemiological studies, 15 or more cigarettes per day was associated with a significantly increased risk) and is quite marked in women over 35 years of age. Women who use oral contraceptives should be strongly advised not to smoke.

Available only to the public health sector (including family planning clinics; college and university health centers; community health centers; and city, county, state, and federal facilities), and authorized, non-retail prescribers, Afaxys Pharmaceuticals products are now covered under all fee for service Medicaid plans and commercial managed-care formularies.

Additionally, the company distributes ella® (ulipristal acetate), an emergency contraceptive available by prescription only to all prescribers, nationwide.

About Afaxys Pharmaceuticals
Afaxys, Inc. (www.afaxys.com) is a strategic sourcing company whose mission is to serve family planning providers who are part of the country's public health system. Since 2005, the management of Afaxys has operated a Group Purchasing Organization (https://gpo.afaxys.com/) which negotiates favorable pricing across a broad base of mission-critical products and services for its members. In 2012, a second division, Afaxys Pharmaceuticals (www.afaxys.com/pharma) was launched and this brought a portfolio of low-cost, quality generic oral contraceptives to the public health market. As a whole, Afaxys' mission is to provide customers affordable, reliable access to the products and services they need to care for their patients. Afaxys believes that no healthcare clinic should have to choose between high inventory costs and providing necessary services to patients in need. Afaxys manages the supply needs of customers so they can focus on what they do best: caring for patients. Visit www.afaxys.com for more information on the services and products that Afaxys offers.

Note: This press release was issued in the United States and is intended as reference information for U.S. journalists and customers. The information contained in this Afaxys press release is accurate at the time of issuance, and the company assumes no responsibility for updating the information to reflect subsequent developments.


Media Contact:
Colleen Troy
Touchpoint Communications
Email Contact